BIOSPLICE THERAPEUTICS
Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Samumed adopted a fresh operating philosophy from the beginning — one based on a goal of building a broad technology platform aimed at modulating regenerative pathways to improve patient health.
BIOSPLICE THERAPEUTICS
Industry:
Biotechnology Health Care Life Science
Founded:
2008-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.biosplice.com
Total Employee:
51+
Status:
Active
Contact:
8589529303
Email Addresses:
[email protected]
Total Funding:
778 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager Google Universal Analytics Global Site Tag Mobile Non Scaleable Content US Privacy User Signal Mechanism ASP.NET Google Analytics 4
Similar Organizations
Aspect Biosystems
Biotech company developing bioprinted tissue therapeutics to transform how we treat disease.
Autobahn Therapeutics
Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.
Aviceda Therapeutics
Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases.
EvolveImmune Therapeutics
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies.
Hopewell Therapeutics
Hopewell Therapeutics is a Synthetic Lipid-based drug delivery company for gene therapy and gene editing.
Lycia Therapeutics
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Nectin Therapeutics
Nectin Therapeutics is a startup company dedicated to the development of next generation immuno-oncology antibodies.
PhenoVista Biosciences
PhenoVista Biosciences provides high content imaging-based phenotypic assay development and screening services.
Rondo Therapeutics
Rondo Therapeutics creates novel bispecific antibodies that activate the immune system to fight cancer.
Seismic Therapeutic
Seismic Therapeutic is a biotechnology company advancing machine learning for immunology drug development.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Spartan Bioscience
Spartan Bioscience designs and manufactures sample-to-result DNA testing systems.
Twist Bioscience
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sands Capital Ventures
Sands Capital Ventures investment in Venture Round - Biosplice Therapeutics
Verition Fund Management
Verition Fund Management investment in Venture Round - Biosplice Therapeutics
Eventide
Eventide investment in Venture Round - Biosplice Therapeutics
aMoon Fund
aMoon Fund investment in Venture Round - Biosplice Therapeutics
Symbiosis Group
Symbiosis Group investment in Venture Round - Biosplice Therapeutics
Cem Ortabaş
Cem Ortabaş investment in Series C - Biosplice Therapeutics
Starling Group
Starling Group investment in Series B - Biosplice Therapeutics
Vickers Venture Partners
Vickers Venture Partners investment in Series B - Biosplice Therapeutics
Swicorp
Swicorp investment in Series B - Biosplice Therapeutics
Polar Light Ventures
Polar Light Ventures investment in Series A - Biosplice Therapeutics
Official Site Inspections
http://www.biosplice.com Semrush global rank: 3.53 M Semrush visits lastest month: 4.19 K
- Host name: 40.118.101.67
- IP address: 40.118.101.67
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Biosplice Therapeutics"
Mission - Biosplice
Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Our scientific platform is based on biological discoveries that govern tissue …See details»
Biosplice Therapeutics - Crunchbase Company Profile …
Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of …See details»
Biosplice Therapeutics - LinkedIn
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation ...See details»
Biosplice Therapeutics - Wikipedia
Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California. [1] It was founded in 2008 by Osman Kibar. [2]Samumed's …See details»
Biosplice Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap
Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (completed Phase 3) and cirtuvivint for numerous cancers, with a broad preclinical pipeline that encompasses …See details»
Biosplice Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Clinical Studies | Biosplice
Biosplice is committed to developing safe and effective medical solutions to help patients. Biosplice may, in the future, provide access to its investigational drug products for expanded …See details»
Biosplice Therapeutics Announces Department of Defense (DoD) …
Mar 8, 2024 About Roskamp: Since opening its doors in 2003, The Roskamp Institute, a 501(c)(3) nonprofit organization, has been a leader in the global effort to better understand …See details»
Biosplice Presents Successful Structure and Pain
Nov 13, 2023 Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to ...See details»
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small …See details»
Biosplice Announces Upcoming Presentation of Successful OA-07 …
Apr 18, 2024 Biosplice will present its OA-07 results at the Osteoarthritis Research Society International (“OARSI”) World Congress, April 18-21, 2024, in Vienna, Austria.See details»
After reaching a high with $12B valuation, Biosplice lays off staff …
Feb 8, 2022 After reaching a $12 billion valuation in 2018, Biosplice appears to be falling back down to Earth, and its workforce is taking the brunt. The company is laying off 41 workers, …See details»
Osteoarthritis - Biosplice
Biosplice Therapeutics is proud to be a Corporate Member of OARSI, the leading medical society for advancing the understanding, early detection, treatment, and prevention of osteoarthritis …See details»
Haisco to pay $140M to get the ball rolling on Biosplice's phase 3 ...
Sep 15, 2021 Biosplice Therapeutics is attempting to clear its late-stage knee osteoarthritis treatment after other biopharmas have reached snags in the past year, and it now has $140 …See details»
Biosplice Announces Interim Data from Phase 3 Long-Term
Dec 15, 2022 Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s …See details»
Biosplice Presents Successful Structure and Pain Results from …
Nov 13, 2023 Biosplice Therapeutics, Inc. Robust three-year X-ray results of medial joint space width (mJSW) and significant pain response in patients highlight the potential of lorecivivint to …See details»
News - Biosplice
Apr 15, 2021 Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance its Alternative Splicing Platform: 2020. Date Title; Dec 01 Darrin M. Beaupre, M.D., Ph.D. joins …See details»
Publications - Biosplice
Biosplice Therapeutics has widely presented its science and data. Please choose the area of interest below to view a sampling of these publications. Filter. Radiographic and Pain …See details»
Biosplice Announces Interim Data from Phase 3 Long-Term …
Dec 15, 2022 Biosplice Therapeutics, Inc. Unique interim X-ray results from an ongoing long-term extension study suggest structure-modifying benefit of repeat injections of lorecivivint, as …See details»